Gsk plc GSK.US Overview Analysis
)GSK AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock holds a moderate value rating. If you have positions, consider retaining; for new ones, wait for a value score above 4.
GSK Current Performance
2.57%
Gsk plc
-0.60%
Avg of Sector
-0.01%
S&P500
Top 10 High Relevance to GSK
- SNY Sanofi s.a.Value 3Trend 2Swing Trading 2Whale Interest 2Dividend 5See more
GSK Profile
GSK plc is a global biopharma company. The Company's segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes the lead molecule IDRX-42, highly selective tyrosine kinase inhibitor (TKI) that is designed to improve patients with gastrointestinal stromal tumors (GIST).